Vaylen vs Maximus: Compounded GLP-1 Pricing and Services Compared
Vaylen vs Maximus pits a prepaid, multiformat compounded GLP 1 platform against a straightforward monthly semaglutide service. Early verdict: Vaylen emphasizes lower annualized rates and multiple formats but requires full upfront payment for 12 month plans; Maximus offers a simple flat monthly price without prepaid requirements.
How the two providers differ at a glance
Compare Vaylen and Maximus across price model, medication formats, payment timing and refund policies, clinical review and availability, and regulatory disclosures. These five differences are the most distinctive based on the available evidence.
1. Price model and billing timing
Vaylen publishes annualized headline rates on 12 month plans that are billed upfront. Semaglutide injections are shown as $83.25 per month on the 12 month plan, which equals a single upfront charge of $999, with monthly options also displayed as $224 per month. Vaylen states the 12 month rates are billed in one charge and that you pay before a clinician review.
Maximus presents a flat direct pay monthly rate of $132.99 per month without a prepaid requirement described in the supplied evidence. Maximus emphasizes a simple monthly charge and no membership fees.
2. Medication formats and molecule options
Vaylen offers three formats and two molecules: weekly semaglutide injections, daily oral semaglutide tablets, and weekly tirzepatide injections. The vendor highlights both injectable and needle free tablet formats on one platform so a clinician can switch medication types without changing providers. Maximus, in the supplied evidence, focuses on compounded once weekly semaglutide injections and does not publish comparable detail on tirzepatide or an oral tablet option.
3. Refunds and approval process
Vaylen requires payment before clinician review but states it provides a full refund for that billing cycle if a clinician declines to prescribe. The evidence notes clinician review is bundled into the plan price and typically completed within 24 hours.
Maximus also states that if you are not approved for treatment, medication costs will be fully refunded. Maximus frames its process as telemedicine with prescriptions approved by licensed doctors and filled through U.S. pharmacies.
4. Clinical access and turnaround
Vaylen advertises telehealth consultations by live video or asynchronous review with licensed U.S. clinicians via OpenLoop Health, clinician review within 24 hours, and clinician approval determining clinical appropriateness. Maximus offers convenient telemedicine access with prescriptions approved by licensed doctors and does not require in person visits. Both describe telemedicine and licensed clinicians in the supplied evidence.
5. Availability, shipping, and regulatory disclosure
Vaylen states free discreet shipping in 1 to 3 business days, availability in all 50 states, HIPAA protection, and Legitscript certification. Vaylen also notes that its compounded medications are not FDA approved finished products and are not reviewed by FDA for safety, effectiveness, or quality.
Maximus highlights free expedited or priority shipping and that prescriptions are filled through trusted U.S. pharmacies. Maximus notes compounded medications are not FDA approved finished products in the captured regulatory language as well. Maximus is available in all 50 states except Mississippi in the supplied evidence.
Comparison table: Vaylen vs Maximus
| Criteria | Vaylen | Maximus |
|---|---|---|
| Starting price shown | $83.25/mo on 12 month semaglutide plan | $132.99/mo flat rate |
| Billing model | 12 month plans billed upfront; month to month alternative shown | Direct pay monthly, no prepaid plan described |
| Medication formats | Semaglutide injections, oral semaglutide tablets, tirzepatide injections | Compounded weekly semaglutide injections |
| Refund if not approved | Full refund for that billing cycle if clinician declines | Medication costs fully refunded if not approved |
| Turnaround and access | Clinician review within 24 hours; telehealth live or asynchronous | Telemedicine with licensed doctors; no clinic visits required |
| Shipping | Free discreet shipping in 1 to 3 business days | Free priority or expedited shipping |
| Availability | Available in all 50 states | Available in all 50 states except Mississippi |
| Regulatory note | All medications are compounded and not FDA approved finished products | Compounded medications not FDA approved finished products |
Practical differences that matter
If you want the lowest headline monthly rate on a prepaid annual plan and access to oral semaglutide or tirzepatide without switching providers, Vaylen supports those choices. That comes with the trade off of prepaying a full year before clinician review, but Vaylen states a full refund is provided if you are declined.
If you prefer a simple monthly payment and a straightforward semaglutide injection program billed month to month, Maximus presents a flat $132.99 per month model with prescriptions filled through U.S. pharmacies and no described prepaid requirement in the supplied facts.
Conclusion: Choose based on payment model and format needs
Vaylen vs Maximus narrows to whether you value lower annualized prepaid pricing and multiple medication formats or prefer a straightforward monthly direct pay plan focused on semaglutide injections. Both operate via telemedicine, use licensed clinicians, ship from U.S. pharmacies or partners, and rely on compounded medications that are not FDA approved finished products.
Sign up for Maximus monthly plan
Explore Vaylen formats and prepaid plans
Choose Vaylen if you are a decisive buyer comfortable prepaying a 12 month plan to access the lowest effective monthly rate shown and want injectable and oral semaglutide plus tirzepatide on one platform. Choose Maximus if you prefer a simple direct pay monthly semaglutide program with prescriptions filled through trusted U.S. pharmacies and no prepaid annual charge described in the available evidence.